243 related articles for article (PubMed ID: 17005842)
1. In vitro susceptibility of breakthrough Candida bloodstream isolates correlates with daily and cumulative doses of fluconazole.
Clancy CJ; Staley B; Nguyen MH
Antimicrob Agents Chemother; 2006 Oct; 50(10):3496-8. PubMed ID: 17005842
[TBL] [Abstract][Full Text] [Related]
2. Antifungal susceptibility testing of fluconazole by flow cytometry correlates with clinical outcome.
Wenisch C; Moore CB; Krause R; Presterl E; Pichna P; Denning DW
J Clin Microbiol; 2001 Jul; 39(7):2458-62. PubMed ID: 11427554
[TBL] [Abstract][Full Text] [Related]
3. Triazole cross-resistance among Candida spp.: case report, occurrence among bloodstream isolates, and implications for antifungal therapy.
Magill SS; Shields C; Sears CL; Choti M; Merz WG
J Clin Microbiol; 2006 Feb; 44(2):529-35. PubMed ID: 16455909
[TBL] [Abstract][Full Text] [Related]
4. Empirical treatment of candidemia in intensive care units: fluconazole or broad-spectrum antifungal agents?
Guinea J; Peláez T; Rodríguez-Créixems M; Torres-Narbona M; Muñoz P; Alcalá L; Bouza E
Med Mycol; 2009; 47(5):515-20. PubMed ID: 18972315
[TBL] [Abstract][Full Text] [Related]
5. Distribution and antifungal susceptibility of Candida species causing candidemia from 1996 to 1999.
Cheng MF; Yu KW; Tang RB; Fan YH; Yang YL; Hsieh KS; Ho M; Lo HJ
Diagn Microbiol Infect Dis; 2004 Jan; 48(1):33-7. PubMed ID: 14761719
[TBL] [Abstract][Full Text] [Related]
6. Fluconazole MIC and the fluconazole dose/MIC ratio correlate with therapeutic response among patients with candidemia.
Clancy CJ; Yu VL; Morris AJ; Snydman DR; Nguyen MH
Antimicrob Agents Chemother; 2005 Aug; 49(8):3171-7. PubMed ID: 16048920
[TBL] [Abstract][Full Text] [Related]
7. Geographic and temporal trends in isolation and antifungal susceptibility of Candida parapsilosis: a global assessment from the ARTEMIS DISK Antifungal Surveillance Program, 2001 to 2005.
Pfaller MA; Diekema DJ; Gibbs DL; Newell VA; Ng KP; Colombo A; Finquelievich J; Barnes R; Wadula J;
J Clin Microbiol; 2008 Mar; 46(3):842-9. PubMed ID: 18199791
[TBL] [Abstract][Full Text] [Related]
8. Take control over your fluconazole prescriptions: the growing importance of Candida glabrata as an agent of candidemia in Brazil.
Pasqualotto AC; Zimerman RA; Alves SH; Aquino VR; Branco D; Wiltgen D; do Amaral A; Cechinel R; Colares SM; da Rocha IG; Severo LC; Sukiennik TC
Infect Control Hosp Epidemiol; 2008 Sep; 29(9):898-9. PubMed ID: 18785850
[No Abstract] [Full Text] [Related]
9. Candida glabrata and Candida krusei fungemia after high-risk allogeneic marrow transplantation: no adverse effect of low-dose fluconazole prophylaxis on incidence and outcome.
Safdar A; van Rhee F; Henslee-Downey JP; Singhal S; Mehta J
Bone Marrow Transplant; 2001 Nov; 28(9):873-8. PubMed ID: 11781648
[TBL] [Abstract][Full Text] [Related]
10. Breakthrough Candida krusei fungemia during fluconazole prophylaxis followed by breakthrough zygomycosis during caspofungin therapy in a patient with severe aplastic anemia who underwent stem cell transplantation.
Girmenia C; Moleti ML; Micozzi A; Iori AP; Barberi W; Foà R; Martino P
J Clin Microbiol; 2005 Oct; 43(10):5395-6. PubMed ID: 16208029
[TBL] [Abstract][Full Text] [Related]
11. Evolution of antifungal susceptibility among Candida species isolates recovered from human immunodeficiency virus-infected women receiving fluconazole prophylaxis.
Vazquez JA; Peng G; Sobel JD; Steele-Moore L; Schuman P; Holloway W; Neaton JD
Clin Infect Dis; 2001 Oct; 33(7):1069-75. PubMed ID: 11528582
[TBL] [Abstract][Full Text] [Related]
12. Candidemia in a tertiary care cancer center: in vitro susceptibility and its association with outcome of initial antifungal therapy.
Antoniadou A; Torres HA; Lewis RE; Thornby J; Bodey GP; Tarrand JP; Han XY; Rolston KV; Safdar A; Raad II; Kontoyiannis DP
Medicine (Baltimore); 2003 Sep; 82(5):309-21. PubMed ID: 14530780
[TBL] [Abstract][Full Text] [Related]
13. Rationale for reading fluconazole MICs at 24 hours rather than 48 hours when testing Candida spp. by the CLSI M27-A2 standard method.
Ostrosky-Zeichner L; Rex JH; Pfaller MA; Diekema DJ; Alexander BD; Andes D; Brown SD; Chaturvedi V; Ghannoum MA; Knapp CC; Sheehan DJ; Walsh TJ
Antimicrob Agents Chemother; 2008 Nov; 52(11):4175-7. PubMed ID: 18809944
[TBL] [Abstract][Full Text] [Related]
14. Candidaemia associated with decreased in vitro fluconazole susceptibility: is Candida speciation predictive of the susceptibility pattern?
Oxman DA; Chow JK; Frendl G; Hadley S; Hershkovitz S; Ireland P; McDermott LA; Tsai K; Marty FM; Kontoyiannis DP; Golan Y
J Antimicrob Chemother; 2010 Jul; 65(7):1460-5. PubMed ID: 20430790
[TBL] [Abstract][Full Text] [Related]
15. Community-acquired fungemia due to a multiple-azole-resistant strain of Candida tropicalis.
Jandourek A; Brown P; Vazquez JA
Clin Infect Dis; 1999 Dec; 29(6):1583-4. PubMed ID: 10585825
[No Abstract] [Full Text] [Related]
16. In vitro susceptibilities of bloodstream isolates of Candida spp.: results from a multicenter active surveillance program in Andalusia.
Flórez C; Martín-Mazuelos E; Ruiz M; Cisneros JM; Herrero M; García MV; Márquez M; Porras J; Martín P; Gamero C; Castón JJ;
Enferm Infecc Microbiol Clin; 2009 Nov; 27(9):518-22. PubMed ID: 19477048
[TBL] [Abstract][Full Text] [Related]
17. Breakthrough fungaemia in neonates and infants caused by Candida albicans and Candida parapsilosis susceptible to fluconazole in vitro.
Krcmery V; Huttova M; Mateicka F; Laho L; Jurga L; Ondrusova A; Tarekova Z; Kralinsky K; Hanzen J; Liskova A; Mrazova M; Sabo A; Pisarcikova M; Kovacicova G; Chovancova D; Szovenyiova Z
J Antimicrob Chemother; 2001 Oct; 48(4):521-5. PubMed ID: 11581231
[TBL] [Abstract][Full Text] [Related]
18. [Multicenter study of fungemia due to yeasts in Argentina].
Rodero L; Davel G; Soria M; Vivot W; Córdoba S; Canteros CE; Saporiti A;
Rev Argent Microbiol; 2005; 37(4):189-95. PubMed ID: 16502638
[TBL] [Abstract][Full Text] [Related]
19. High-dose fluconazole therapy for cancer patients with solid tumors and candidemia: an observational, noncomparative retrospective study.
Torres HA; Kontoyiannis DP; Rolston KV
Support Care Cancer; 2004 Jul; 12(7):511-6. PubMed ID: 14986077
[TBL] [Abstract][Full Text] [Related]
20. Activities of fluconazole and voriconazole against bloodstream isolates of Candida glabrata and Candida krusei: a 14-year study in a Spanish tertiary medical centre.
Quindós G; Sánchez-Vargas LO; Villar-Vidal M; Eraso E; Alkorta M; Hernández-Almaraz JL
Int J Antimicrob Agents; 2008 Mar; 31(3):266-71. PubMed ID: 18054468
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
